🔗 Share this article

As the United States undertakes unprecedented adjustments to its immunization guidelines, a particular individual appears in a surprising turn: Høeg, a US-based sports medicine doctor and epidemiologist who first made her name by questioning COVID-19 vaccines in the global health crisis and has focused upon potential fatalities following COVID-19 immunization in her brief time at the FDA.

Planned Changes to Pediatric Vaccine Schedule

Public health authorities had intended to unveil radical revisions to the pediatric vaccination calendar in December, bringing the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US out of alignment with much of the global community with no evidence for improved outcomes. This reveal has been postponed until the new year.

Rather than the top vaccines chief, Tracy Beth Høeg is set to speak at the meeting. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the division this calendar year.

A Shift at the FDA

The acting appointment could signify a closer partnership between the drug and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it points to a greater focus upon rolling back previously authorized vaccines at the FDA.

Høeg has often pushed for halting specific pediatric immunization guidelines in the US in order to be more in line with Denmark, a nation with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

So far comments, she has kept her attention on vaccination policy – traditionally the domain of Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Doubts Over Qualifications

The appointee has no obvious track record in pharmaceutical research, oversight or administrative roles, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for leading the CDER, remarked Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a sizeable institution. She has no expertise in industry regulation.”

Former directors of the center would “grasp regulatory frameworks and the underlying principles of drug development”, said Janet Woodcock. “Clearly, she has not acquired the type of experience that former directors who headed CBER have had.”

CDER has an immense range of responsibilities at the agency, she stated.

“Many people just focuses on the innovative therapies, but the generic program clears numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and more, and all of those must be managed,” she said. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial administrative aspect to the role, which supervises in excess of 5,000 personnel. “It is a enormous leadership role, if you do it right,” she added.

Official Statement and Controversial Policies

Regarding concerns about Høeg’s credentials and whether this selection represents more teamwork among FDA leaders on immunizations, a press secretary stated that the “questions are based on incorrect presumptions”.

“This background matches the responsibilities of her role,” the representative stated, noting the months Høeg spent advising the FDA commissioner on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Høeg assumes responsibility for the agency head's controversial expedited review system, a disputed one-day therapy clearance system that allegedly troubled her former heads. “How are these medications being chosen for this voucher program? Who takes the decisions?” Howard said. “There is a lot of secrecy going on at the FDA right now.”

Overall, he said, “the FDA appears to be shifting towards more relaxed rules of pharmaceuticals, aside from vaccines.”

Public History on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if concerning, history, critics observe. She published a analysis using unconfirmed volunteer-provided data to determine the frequency of myocarditis after COVID-19 immunization. She counseled the Florida top health official Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the current federal leadership featured altering guidelines for novel immunizations and ending “optional” vaccines, she said following the vote on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of preventing adolescent males from obtaining Covid vaccinations.

“She’s an thorough true believer who commences with her preconceived notions and reverse-engineers to accommodate the data in a very misleading, dishonest fashion,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow contrarians, {like|